Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H23F3N4O |
| Molecular Weight | 440.4608 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1C[C@H](N)C[C@@H](C1)C2=C(NC(=O)C3=NC(=C(F)C=C3)C4=C(F)C=CC=C4F)C=NC=C2
InChI
InChIKey=VRQXRVAKPDCRCI-ZNMIVQPWSA-N
InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1404
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C106259
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | |||
|
1210608-43-7
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | |||
|
LGH-447
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | MedKoo CAT NO: 407201, CAS NO: 1210608-43-7Description: PIM447, also known as LGH447, is a potent Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitor. Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. PIM447 demonstrates in vivo target modulation (pS6RP), single agent antitumor activity in a KG-1 AML mouse xenograft model, and druglike properties suitable for development. PIM447 advanced into humans in 2012 and is currently being assessed in several phase I trials. (last updated: 6/17/2016). | ||
|
100000178339
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | |||
|
9TG5O4V25H
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | |||
|
CHEMBL3545194
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | |||
|
SUB194067
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | |||
|
DB14943
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY | |||
|
44814409
Created by
admin on Sat Dec 16 11:20:59 UTC 2023 , Edited by admin on Sat Dec 16 11:20:59 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
